Why Digitalisation Is Long Overdue For The Life Sciences Industry?
BioSpectrum Asia|December 2020
During the early stages of novel coronavirus (COVID-19) outbreak, there was a lot of anticipation over the “return to normal” once a vaccine had been discovered. Analysts had predicted a “V-shaped” economic bounce-back from as early as fall 2019. But the reality has been far more sobering; government scientists and medical experts now express “cautious optimism” that a reliable candidate might only be available to the public in early 2021, with a stronger likelihood of its launch in the later part of the year.
Why Digitalisation Is Long Overdue For The Life Sciences Industry?

Pierre Kardasz, Asia Pacific Regional Industry Manager, Consumer Packaged Goods and Life Sciences, Rockwell Automation Inc., Singapore

Once a rare occurrence, epidemics are set to become a regular part of this century due to prevalent urbanisation, globalisation, and factory farms. Taking lab testing, human trials, and various rounds of scientific, commercial, and regulatory approvals into account, experimental drugs average a span of 12 years to hit the market. Hence, speed and efficiency are of the essence to sustain a rapidly interconnected population and yet there must be no compromises to safety and quality.

The long-term solution to this quandary is no different from that of all modern enterprises – organisations that have embraced digital transformation are better positioned to adapt to immediate demands while maintaining production of other critical items.

Competitive market demands require higher yields, superior quality, and greater throughput. This can lead to increasingly complicated assembly systems, higher compliance costs, and strain on overloaded systems. Smart workflow automation comprised of intuitive, intelligent and integrative solutions. Medical device manufacturing companies are driven by immense pressures to help ensure safety, accuracy, and regulatory compliance throughout the production process. Similarly, intense competition, higher production requirements, and a strict regulatory environment place pressure on pharma manufacturers to optimize production. Hence, real-time access and extended enterprise visibility to vital manufacturing data is essential. A smart, connected plant that is built on an integrated, flexible, automation system can deliver high business values by accelerating production scale.

Denne historien er fra December 2020-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra December 2020-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIOSPECTRUM ASIASe alt
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024